本文選題：普羅布考 + 動脈粥樣硬化��； 參考：《生物化學與生物物理進展》2015年09期

【摘要】：作為一種有效的降脂藥物,普羅布考能夠降低血漿高密度脂蛋白膽固醇(HDL-C)水平并抑制動脈粥樣硬化,但其機制尚未完全闡明.本研究的目的旨在進一步闡明普羅布考降脂及抗動脈粥樣硬化的機理.將新西蘭白兔隨機分為4組:正常飲食組、正常飲食+普羅布考組、高脂飲食組(HFD組)、高脂飲食+普羅布考組(HFD+P組).結果顯示,處理7周后,與HFD組比較,H FD+P組動脈粥樣硬化病變程度、肝臟脂質蓄積明顯減輕,血漿甘油三脂、總膽固醇、低密度脂蛋白膽固醇及HDL-C水平降低,肝臟中清道夫受體-BⅠ(SR-BⅠ)以及肝臟與小腸中三磷酸腺苷結合盒轉運體(ABC)G5(ABCG5)、ABCG8表達上調,肝臟中A BCA1表達下調,主動脈弓與血漿腫瘤壞死因子α、白介素1、白介素6、單核趨化蛋白1水平降低.這些結果表明普羅布考的抗動脈粥樣硬化作用可能與其調控A BCA1、SR-BⅠ、ABCG5、ABCG8表達及抑制促炎介質的分泌有關.
[Abstract]:As an effective lipid lowering drug, Probucol can reduce plasma high density lipoprotein cholesterol (HDL-C) and inhibit atherosclerosis, but its mechanism has not been fully elucidated. The aim of this study was to further elucidate the mechanism of probucol's lipid lowering and anti-atherosclerosis. New Zealand white rabbits were randomly divided into 4 groups: normal diet group, normal diet probucol group, high fat diet group (HFD group) and high fat diet probucol group (HFD group). The results showed that compared with HFD group, the degree of atherosclerosis, hepatic lipid accumulation, plasma triglyceride, total cholesterol, low density lipoprotein cholesterol and HDL-C levels were significantly decreased in H FD P group after 7 weeks of treatment. The expression of scavenger receptor -B 鈪，

本文編號：2056176